

**ANNUAL
REPORTS IN
MEDICINAL
CHEMISTRY
Volume 42**

*Sponsored by the Division of Medicinal Chemistry
of the American Chemical Society*

Editor-in-Chief: JOHN E. MACOR

BRISTOL-MYERS SQUIBB, R&D
WALLINGFORD, CT, USA



Boehringer Ex. 2012

Annual Reports in
MEDICINAL CHEMISTRY

VOLUME **42**

*Sponsored by the Division of Medicinal Chemistry
of the American Chemical Society*

Editor-in-Chief

JOHN E. MACOR
*Neuroscience Discovery Chemistry
Bristol-Myers Squibb
Wallingford, CT, United States*

Section Editors

**ROBICHAUD • STAMFORD • BARRISH • MYLES •
LOWE • DESAI**



Amsterdam • Boston • Heidelberg • London • New York • Oxford
Paris • San Diego • San Francisco • Singapore • Sydney • Tokyo
Academic Press is an imprint of Elsevier



Boehringer Ex. 2012

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

Academic Press is an imprint of Elsevier
84 Theobald's Road, London WC1X 8RR, UK
Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands
Linacre House, Jordan Hill, Oxford OX2 8DP, UK
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA
525 B Street, Suite 1900, San Diego, CA 92101-4495, USA

First edition 2007

Copyright © 2007 Elsevier Inc. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: permissions@elsevier.com. Alternatively you can submit your request online by visiting the Elsevier web site at <http://www.elsevier.com/locate/permissions>, and selecting *Obtaining permission to use Elsevier material*

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

ISBN: 978-0-12-373912-4

ISSN: 0065-7743

For information on all Academic Press publications
visit our website at books.elsevier.com

Printed and bound in USA

07 08 09 10 11 10 9 8 7 6 5 4 3 2 1

Working together to grow
libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER BOOK AID International Sabre Foundation



Cor

Prei

CHAP

CHAP

CHAP

Boehringer Ex. 2012

CHAPTER 7

Case History: JANUVIA™ (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Ann E. Weber* and Nancy Thornberry**

Contents	1. Introduction	95
	2. Pathogenesis of Type 2 Diabetes	96
	3. Rationale for the Use of DPP-4 Inhibitors to Treat Type 2 Diabetes	97
	4. MRL's DPP-4 Inhibitor Program: <i>Threo</i> - and <i>Allo</i> -Isoleucyl Thiazolidides	98
	5. Medicinal Chemistry Efforts Leading to Sitagliptin	100
	5.1 Program objectives	100
	5.2 α -Amino acid derived DPP-4 inhibitors	100
	5.3 High throughput screening hits	101
	5.4 SAR in the β -aminoacyl amide series	102
	5.5 SAR in the piperazine series	103
	6. Properties of Analog 27 and Sitagliptin	105
	7. Clinical Studies of Sitagliptin	106
	8. Conclusion	107
	References	107

1. INTRODUCTION

Diabetes is a global epidemic affecting more than 240 million people worldwide. The incidence of this disease is growing at an alarming rate, with 380 million cases predicted by 2025. Each year over 3.8 million people die from complications of diabetes, including heart disease, stroke and kidney failure. The vast majority

* Department of Medicinal Chemistry, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA

** Department of Metabolic Disorders, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA

Annual Reports in Medicinal Chemistry, Volume 42
ISSN 0065-7743, DOI 10.1016/S0065-7743(07)42007-3

© 2007 Elsevier Inc.
All rights reserved.




Figure 1 JANUVIA™ (sitagliptin).

(90–95%) of cases are type 2 diabetes, largely resulting from the increasing prevalence of obesity and sedentary lifestyles [1].

Despite the availability of a range of agents to treat type 2 diabetes, glucose control remains suboptimal, with less than 50% of patients achieving stated glycemic goals. In addition, current therapies have limited durability and/or are associated with significant side effects such as GI intolerance, hypoglycemia, weight gain, lactic acidosis and edema [2]. Thus, significant unmet medical needs remain. In particular, safer, better tolerated medications which provide increased efficacy and long-term durability are desired. JANUVIA™ (sitagliptin, 1, Figure 1), a dipeptidyl peptidase IV (DPP-4) inhibitor, represents a promising new approach to the treatment of this disease.

2. PATHOGENESIS OF TYPE 2 DIABETES

The pathogenesis of type 2 diabetes involves a set of three primary defects: insulin resistance, insulin secretory dysfunction, and hepatic glucose overproduction. Insulin resistance is a common predisposing defect, and is believed to occur as a consequence of obesity in most individuals. As long as an individual maintains insulin secretion adequate to compensate for insulin resistance, plasma glucose levels remain normal; however, if β -cell function declines, and the pancreas is no longer able to produce adequate amounts of insulin to compensate for the insulin resistance, hyperglycemia – and subsequently, diabetes mellitus – results. Not only does this β -cell defect lead to hyperglycemia and the onset of diabetes, the progressive decline in β -cell function during the course of diabetes leads to the need for more and more complex treatment regimens to manage glucose control in diabetic patients, and ultimately, to the need for insulin. As expected from the pathogenesis of type 2 diabetes, therapies that increase the circulating concentrations of insulin have proven therapeutically beneficial in the treatment of type 2 diabetes [2]. Indeed, sulfonylureas and related insulin secretagogues currently represent 42% of the total worldwide oral market, with sales in excess of \$1.7 billion, notwithstanding mechanism-based side effects of hypoglycemia and weight gain. In addition, current insulin secretagogues commonly fail to maintain adequate glycemic control, and may contribute to the progressive decline in β -cell function. Thus, current unmet medical needs in the treatment of type 2 diabetes include insulin secretagogues which are

glucos
to wei

3. RA DI/

Inhibit
proach
part, a
agents
inhibit
via sta
has a
tion. C
logs to
fasting
result
stantia
agonis
specie
taneol
opme
the cc
DI

avale
incre
are b
hypo
led to
throu
or at
ficial
and s
Ea
inhib
inclu
or “k
hum
tions
[8,9].
com
culat
anim
In 19
inde
pour

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.